Lifcin125 mg/5 ml

Lifcin 125 mg/5 ml is indicated for the treatment of respiratory tract infections including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia and nosocomial pneumonia. It is also used in the treatment of uncomplicated and complicated skin & soft tissue infections, chronic bacterial prostatitis and uncomplicated & complicated urinary tract infections (mild to moderate). lt is indicated for the treatment of adults (18 years of age).

4-Quinolone preparations

Lifcin 125 mg/5 ml is a synthetic, broad-spectrum, third generation fluoroquinolone antibiotic. Chemically, Lifcin 125 mg/5 ml is a chiral fluorinated carboxyquinolone. Lifcin 125 mg/5 ml exerts antibacterial action by inhibiting bacterial topoisomerase IV and DNA gyrase, the enzymes required for DNA replication, transcription repair and recombination. It has in vitro activity against a wide range of gm-ve and gm+ve microorganisms.

Acute sinusitis: 500 mg daily for 10-14 days.Acute exacerbations of chronic bronchitis: 250-500 mg daily for 7-10 days.Community-acquired pneumonia: 500 mg once or twice daily for 7-14 days.Nosocomial pneumonia: 750 mg once daily for 7-14 days.Skin & soft tissue infections: 500 mg once or twice daily for 7-14 days.Chronic prostatitis: 500 mg once daily for 28 days.Urinary tract infections: 250 mg daily for 7-10 days (for 3 days in uncomplicated infections).

Antacids, iron and adsorbents reduce absorption of Lifcin 125 mg/5 ml. NSAIDs may increase the risk of CNS stimulation. Warfarin may increase the risk of bleeding.

Lifcin 125 mg/5 ml is contraindicated in patients with a history of hypersensitivity to Lifcin 125 mg/5 ml and other quinolone antimicrobial agents or any other components of this product.

Lifcin 125 mg/5 ml is generally well tolerated. However, a few side effects can usually be seen. Side effects include nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). Side effects that may be seen very rarely include- tremors, depression, anxiety, confusion etc.

US FDA pregnancy category of Lifcin 125 mg/5 ml is C. So, Lifcin 125 mg/5 ml should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.

Adequate amount of water should be taken during treatment period to avoid concentrated form of urine. Dose adjustment is required for patients with impaired renal function.

Keep in a dry place away from light and heat. Keep out of reach of children.